|
| Thursday, 29 November 2018, 14:48 JST | |
| |  | |
Source: Eisai | |
|
|
|
|
| -The First Polyethylene Glycol Preparation for Chronic Constipation in Japan- |
TOKYO, Nov 29, 2018 - (JCN Newswire) - EA Pharma Co., Ltd., EA Pharma's parent company Eisai Co., Ltd. and Mochida Pharmaceutical Co., Ltd. announced today that the constipation treatment "MOVICOL" (Development code AJG555) was included in Japan's National Health Insurance drug price list as of November 20, 2018, and EA Pharma and Mochida launched the product onto the Japan market today.MOVICOL is the first polyethylene glycol preparation indicated for treatment of chronic constipation(1) in Japan, available for adults and children 2 years of age and older. MOVICOL increases the moisture in the intestinal tract by osmolality of its main ingredient polyethylene glycol (macrogol 4000), which increases fecal moisture, softens feces, increases fecal volume and physiologically activates the peristaltic movement of the colon to promote bowel movement. Furthermore, MOVICOL is a powdered medicine to be dissolved in water before administration, which enables suitable increase or decrease of the dose to obtain the preferred stool consistency.
Outside Japan, this product has been marketed mainly in Europe by Norgine B.V. under the brand name MOVICOL and is used by many patients with chronic constipation. In Japan, the Evaluation Committee on Unapproved or Off-Labeled Drugs with High Medical Needs(2)) of Ministry of Health, Labour and Welfare recognized the "high unmet medical needs" of polyethylene glycol preparations for chronic constipation, and Ajinomoto Pharmaceuticals Co., Ltd. (now EA Pharma) developed this product with Mochida for oral chronic constipation treatment in pediatric and adult patients in Japan under the license granted by Norgine to Ajinomoto Pharmaceuticals Co., Ltd. (now EA Pharma).
In a placebo-controlled double-blind PIII clinical trial in adults conducted in Japan, the MOVICOL group demonstrated a statistically significant increase in spontaneous bowel movement frequency(3)) (the primary endpoint) compared to the placebo group. In the subsequent 52-week consecutive administration period, the spontaneous bowel movement frequency was steadily maintained in most cases. In a PIII clinical trial (a baseline-controlled open-label study) in pediatric patients, a statistically significant increase in spontaneous bowel movement frequency (the primary endpoint) was observed compared to baseline. The major adverse drug reactions in these trials were diarrhea and abdominal pain.
EA Pharma and Mochida have commenced distribution of the product under the same brand name in Japan. EA Pharma and Eisai jointly provide information for the proper use of MOVICOL under a co-promotion agreement.
The prevalence of constipation is high in young women and both elderly men and women, and the symptoms can become severe particularly in pediatric patients. The symptoms of constipation include reduced bowel movement, feeling of incomplete evacuation, and hard stools. When the symptoms become chronic, many patients suffer from a decline of QOL (Quality of Life). With the new treatment MOVICOL in addition to "GOOFICE 5 mg Tablet" (bile acid transporter inhibitor for chronic constipation treatment) launched in Japan in April 2018, EA Pharma, Eisai and Mochida are striving to increase treatment options for patients with chronic constipation and diverse disease histories as they seek to further contribute to addressing the needs of, and increasing the benefits provided to, patients, their families and healthcare providers.
(1) Excludingstructuraldisease-inducedconstipation
(2) TheEvaluationCommitteeonUnapprovedorOff-LabeledDrugswithHighMedicalNeeds
This committee was organized in the Ministry of Health, Labour and Welfare to evaluate the medical needs of the drugs and indications that are not approved in Japan ("unapproved or off-labeled drugs") and the appropriateness of filing the public knowledge-based application and requirement of additional studies for filing the marketing and manufacturing application to promote development of unapproved or off-labeled drugs by pharmaceutical companies.
(3) Defecation without use of laxative, enema or manual disimpaction
About "GOOFICE 5 mg Tablet"
"GOOFICE 5 mg Tablet", which EA Pharma in-licensed from Albireo AB (Headquarters, Sweden), is an orally available chronic constipation** treatment having a novel mechanism of action. "GOOFICE 5 mg Tablet" inhibits the bile acid transporter that regulates reabsorption of bile acids thereby increasing the flow of bile acids to the colon, which is expected to enhance colonic motility. EA Pharma and Mochida have a joint development and marketing agreement for "GOOFICE 5 mg Tablet", and started distribution of "GOOFICE 5 mg Tablet" respectively under the same brand name on April 19, 2018 in Japan. EA Pharma also has a co-promotion agreement with Eisai. EA Pharma and Eisai jointly provide information for the proper use of "GOOFICE 5 mg Tablet".
**Excluding structural disease-induced constipation
About EA Pharma Co., Ltd.
EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. for gastrointestinal disease area, was established in April 2016 by integration of the gastrointestinal business unit with more than 60 year's history of the Eisai Group and the gastrointestinal business unit of the Ajinomoto Group having amino acid as its business core. EA Pharma is a gastrointestinal specialty pharma with a full value chain covering R&D, logistics and sales & marketing.
For more information on EA Pharma Co., Ltd., please see http://www.eapharma.co.jp/en/
About Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. has been committed to research and development of innovative pharmaceutical products since its establishment thereby providing distinctive medicines to the medical field. Currently, the core pharmaceutical business focuses resources on the targeted areas of cardiovascular medicine, obstetrics and gynecology, dermatology, psychiatry and gastroenterology, while also providing medicine for intractable disease as well as generics including biosimilars, to meet medical needs.
For more information on Mochida Pharmaceutical Co., Ltd., please see http://www.mochida.co.jp/english/
Contact:
Mochida Pharmaceutical Co., Ltd.
Public Relations
TEL: +81(0)3-3225-6303
EA Pharma Co., Ltd.
Corporate Planning Dept.
TEL: +81(0)3-6280-9802
Eisai Co., Ltd.
PR Dept.
TEL: +81(0)3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| |
| Eisai Related News |
|
| Monday, 23 December 2024, 17:22 JST |
| Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases |
|
| Wednesday, 11 December 2024, 14:45 JST |
| Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia |
|
| Thursday, 5 December 2024, 11:22 JST |
| "LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico |
|
| Thursday, 28 November 2024, 16:26 JST |
| LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea |
|
| Tuesday, 26 November 2024, 15:50 JST |
| Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan |
|
| More news >> |
|
|
|
